Tag: clozapine

Exploring the Impact of COVID-19 Vaccination on Patients Taking Clozapine

Exploring the Impact of COVID-19 Vaccination on Patients Taking Clozapine

| March 1, 2023

by Tammie Lee Demler, PharmD, MBA, BCGP, BCPP; and Carolyn O’Donnell, PharmD, PGY-2  Drs. Demler and O’Donnell are with the New York State Office of Mental Health at Buffalo Psychiatric Center and State University of New York at Buffalo School of Pharmacy and Pharmaceutical Sciences, Department of Pharmacy Practice in Buffalo, New York. Dr. Demler is […]

Continue Reading

High-dose Clozapine Withdrawal: A Case Report and Timeline of a Single Potential Withdrawal Seizure

High-dose Clozapine Withdrawal: A Case Report and Timeline of a Single Potential Withdrawal Seizure

| July 1, 2019

by Megan K. Skelly, PharmD, BCPS; Tammie Lee Demler, BS, PharmD, MBA, BCGP, BCPP; and Claudia Lee, MD Drs. Skelly, Demler, and Lee are with the State University at Buffalo (SUNY) School of Pharmacy and Pharmaceutical Sciences, Department of Pharmacy Practice in Buffalo, New York and Drs. Demler and Lee are also with New York […]

Continue Reading

Atypical Neuroleptic Malignant Syndrome Precipitated By Clozapine And Quetiapine Overdose: A Diagnostic Challenge

Atypical Neuroleptic Malignant Syndrome Precipitated By Clozapine And Quetiapine Overdose: A Diagnostic Challenge

| July 1, 2018 | 0 Comments

By David Choon Liang Teo, MBBS, MRC Psych (UK), FAMS (Psychiatry); Hon Khuan Wong, MBBS; Sheng Neng Tan, MBBS, MMED (Psychiatry), FAMS (Psychiatry) Drs. Teo, Wong and Tan are with the Department of Psychological Medicine, Changi General Hospital, Singapore. Funding: No funding was provided for this article. Disclosures: The authors report no conflicts of interest […]

Continue Reading

Letter to the Editor: Metabolic Changes in Patients with Schizophrenia Switched from Olanzapine to Asenaprine or Clozapine

Letter to the Editor: Metabolic Changes in Patients with Schizophrenia Switched from Olanzapine to Asenaprine or Clozapine

| July 1, 2018 | 0 Comments

By Masaru Nakamura, MD, PhD, and Takahiko Nagamine, MD, PhD Funding/financial disclosures: The author has no conflicts of interest relevant to the content of this letter. No funding was received for the preparation of this letter. Innov Clin Neurosci. 2018;15(7–8):11–14   Dear Editor: The second-generation antipsychotics (SGAs) that focus on dopamine-2 plus serotonin-2A receptor antagonism are first-line treatments […]

Continue Reading